| Private Placement / Financing Transactions
Antares Therapeutics: The company raised $177 million of Series A venture funding in a deal led by Cormorant Asset Management, Omega Funds, Atlas Venture, BVF Partners and Lightspeed Venture Partners on June 10, 2025. Abingworth, Vida Ventures, Invus Opportunities, Tenmile, Vinyanshu Ventures and Willett Advisors also participated in the round. The company is an operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets.
Mosanna Therapeutics: The company raised $80 million of Series A venture funding in a deal led by Pivotal bioVenture Partners, Norwest Holdings, Forbion, Broadview Ventures and EQT Life Sciences on June 9, 2025. Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds also participated in the round. The company is a provider of precision biotech services intended to improve patient outcomes and quality of life in high unmet need diseases.
Ellipsis Health: The company raised $45 million of Series A venture funding in a deal led by CVS Health Ventures, Salesforce and Khosla Ventures on June 12, 2025. E12 Venture Capital, Mitsui Global Investment, Colliers International and AME Cloud Ventures also participated in the round. The company is a developer of an artificial intelligence-powered care management technology designed to automate and enhance clinical operations in healthcare settings.
Exo: The company raised $43.9 million of Series D venture funding in a deal led by Sands Capital, Qubit Health Capital and BOLD Capital Partners on June 11, 2025. Samsung Venture Investment and other undisclosed investors also participated in the round. The company is a developer of a handheld ultrasound device designed for medical imaging and therapeutic applications.
Pharmazz: The company raised an estimated $40 million of Series A venture funding from Sun Pharmaceutical Industries and other undisclosed investors on June 11, 2025, putting the company’s pre-money valuation at $548 million. The company is an operator of a pharmaceutical business intended to focus on discovering, acquiring, developing, and commercializing therapeutics.
Autonomize: The company raised $28.7 million of Series A venture funding through a combination of convertible debt and equity in a deal led by Cigna Ventures, Tau Ventures and Valtruis on June 12, 2025. ATX Venture Partners, Asset Management Ventures and Capital Factory also participated in the round. The company is a developer of an artificial intelligence copilot intended to reduce the administrative burden for healthcare knowledge workers to make data-driven decisions.
Parallel Bio: The company raised $21 million of Series A venture funding in a deal led by AIX Ventures on June 12, 2025. Metaplanet Holdings, Atypical Ventures, Humba Ventures, Amplo, Undeterred Capital, Jeff Dean and Marc Benioff also participated in the round. The company is an operator of a biotechnology company intended to develop immunotherapies, cell therapies, antibody therapies, and vaccines for novel insights into human biology.
Enterome: The company raised $19 million of venture funding from Seventure Partners, SymBiosis Capital Management and Leukemia & Lymphoma Society on June 12, 2025. Primo Capital (Milano) and Institute for Follicular Lymphoma Innovation also participated in the round. The company is a developer of pharmaceuticals and diagnostics tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types.
iView Therapeutics: The company raised $9.2 million of Series A venture funding in a deal led by Chongqing Dian Petrochemical Medical Fund Management on February 24, 2025. Proxima Ventures and Hangzhou Jiurun Investment also participated in the round. The company is a developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology.
Positrigo: The company raised $8.5 million of venture funding in a deal led by HealthCap and NAVIVO Capital on June 10, 2025. The company is a developer of ultra-compact Positron Emission Tomography (PET) systems for functional brain imaging, particularly for diagnosing and monitoring brain disorders like Alzheimer’s disease.
TomBot: The company raised $6.1 million of Series A venture funding in a deal led by Caduceus Capital Partners on June 12, 2025, putting the company’s pre-money valuation at $24 million. Wavemaker Three-Sixty Health also participated in the round. The company is a developer of personal care robots designed to provide therapy for dementia sufferers and help them overcome loneliness and depression.
Rebel Medicine: The company raised $6.1 million of Series A venture funding in a deal led by Crocker Ventures on June 12, 2025. prosperity solutions, Utah Innovation Fund, Joan and Tim Fenton Founders Fund, Cantina Angels, Central Texas Angel Network, S.K. Hart Management and other undisclosed investors also participated in the round. The company is an operator of a pre-clinical specialty pharmaceutical company developing non-opioid solutions for acute pain management.
Enquyst Technologies: The company raised $6 million of venture funding from undisclosed investors on June 13, 2025. The company is a developer of a biotechnology business focused on developing innovative biomanufacturing technologies to improve the process of biological drug manufacturing and reduce costs.
AutonomUS: The company is in the process of raising $5 million of an undisclosed targeted amount of Series A venture funding as of June 13, 2025. The company is a developer of an AI-enabled, ultrasound-guided robotic interventional device for clinicians and first responders.
Carez AI: The company is in the process of raising venture funding on June 9, 2025. The company is a developer of synthetic medical imaging datasets designed to accelerate the training, validation, and regulatory testing of AI in healthcare.
Ceryx Medical: The company raised an undisclosed amount of venture funding in a deal led by Parkwalk Advisors and Development Bank of Wales on June 11, 2025. BGF and Blekinge Business Incubator also participated in the round. The company is a developer of a novel implantable bioelectronics therapeutic device designed to target and treat heart failure.
Fisher Wallace Labs: The company is in the process of raising venture funding on June 13, 2025. The company is a developer of a wearable brain stimulation technology designed to treat depression, anxiety, and insomnia.
Owl Therapeutics: The company is in the process of raising Series A venture funding as of June 10, 2025. The company is a developer of degenerative artificial intelligence and biomarker-powered therapeutics to enhance and protect microglia to clear brain cell debris.
|
